

Dr Geeta Hampson's publications

J. Roberts 1,2, C. Castro 1,2, A.E.B Moore³, I. Fogelman 2,3, G. Hampson 1,2 Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting. *Clin Endocrinol (Oxf)*. 2016 Apr;84(4):509-15

Hampson G, Edwards S, Sankaralingam A, Harrington DJ, Voong K, Fogelman I, Frost ML. Circulating concentrations of vitamin E isomers: Association with bone turnover and arterial stiffness in post-menopausal women. *Bone*. 2015 Dec;81:407-12.

Ishtiaq S, Fogelman I, Hampson G. Treatment of post-menopausal osteoporosis: beyond bisphosphonates. *J Endocrinol Invest*. 2015 Jan;38(1):13-29.

Witham MD, Band MM, Littleford RC, Avenell A, Soiza RL, McMurdo ME, Sumukadas D, Ogston SA, Lamb EJ, Hampson G, McNamee P; BiCARB Study Group. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial. *Trials*. 2015 Aug 1;16:326.

Ishtiaq S, Edwards S, Sankaralingam A, Evans BA, Elford C, Frost ML, Fogelman I, Hampson G. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. *Cytokine*. 2015 Feb;71(2):154-60.

Sankaralingam A, Roplekar R, Turner C, Dalton RN, Hampson G. Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU). *J Osteoporos*. 2014;2014:682763.

Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, Kaski JC, Banerjee D. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. *PLoS One*. 2014 Mar 19;9(3):e91363

P.Mosali 1,2, L.Bernard 1,2, J.Wajed 2, Z.Mohamed 3, M.Ewang 1,3, A.Moore 3, I.Fogelman 2, 3, G.Hampson^{1,2} Vitamin D status and parathyroid hormone (PTH) concentrations influence the skeletal response to Zoledronate and Denosumab. *Calcif Tissue Int* 2014 May;94(5):553-9

Karim Y, Turner C, Dalton N, Roplekar R, Sankaralingam A, Ewang M, Fogelman I, Hampson G. The relationship between pro-resorptive inflammatory cytokines and the effect of high dose vitamin D supplementation on their circulating concentrations. *Int Immunopharmacol*. 2013 Sep 2. doi:pii: S1567-5769(13)00331-7.

D.O'Flaherty, A.Sankaralingam, P. Scully, P.Manghat, D.Goldsmith, G.Hampson. The relationship between intact PTH and bioactive PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD) *Clinical Biochemistry* 2013. doi:pii: S0009-9120(13)00300-7.

Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. *Bone*. 2013 May 20;56(1):42-47.

C.Turner, N.Dalton, R. Inaoui, I.Fogelman, W.D.Fraser, G.Hampson. Effect of a 300,000 I.U loading dose of Ergocalciferol (vitamin D₂) on circulating 1,25 (OH)₂vitamin D and Fibroblast Growth Factor-23 (FGF-23) in vitamin D insufficiency. *J Clin Endocrinol Metab* 2013 Feb;98(2):550-6.

Penny H, Frame S, Dickinson F, Garrett G, Young AR, Sarkany R, Chitalia N, Hampson G, Goldsmith D. Determinants of vitamin D status in long-term renal transplant patients. Clin Transplant. 2012 Nov;26(6): E617-23

G.Hampson, I.Fogelman. The clinical role of bisphosphonate therapy. Int J Womens Health 2012;4:455-69.

S.Thambiah R.Roplekar, P.Manghat, I.Fogelman, W.D. Fraser, D.Goldsmith, G.Hampson .Circulating sclerostin and Dickkopf-1 (DKK1) in pre-dialysis chronic kidney disease (CKD) : relationship with bone density and arterial stiffness . Calcif Tissue Int. 2012 Jun;90(6):473-80.

Sunita K Sandhu, Geeta Hampson. The Diagnosis, Investigation and Management of Osteoporosis: J Clin Pathol. 2011 Dec;64(12):1042-50. Epub 2011 Sep 6. Review.

Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, Chowiencki P, Fogelman I, Nerlander M, Goldsmith D, Hampson G. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone. 2011 May 1;48(5):1127-32.

Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I, Hampson G. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int. 2010 Nov;87(5):398-405.

Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010 Nov; 21(11):1853-61.